The ARCHERY trial, a multi-center prospective validation study involving over 1,000 patients across hospitals in India, South Africa, Jordan, and Malaysia, demonstrates that AI-driven software can generate radiotherapy plans meeting international standards in 95% of cervical cancer cases and 85% of prostate cases. Unlike typical small-scale, single-center AI evaluations prone to bias, this effort stands out for its international scope and focus on LMICs where 94% of cervical cancer deaths occur. The study quality leans toward rigorous prospective assessment rather than a full RCT, with no reported conflicts of interest from UCL and LSHTM investigators. This directly supports the WHO cervical cancer elimination strategy by tackling the radiotherapy access crisis—only 10% coverage in low-income countries—through slashing planning time from days to roughly one hour. Original coverage overlooks key implementation hurdles such as AI model training biases on predominantly high-income datasets, infrastructure integration challenges in rural clinics, and the absence of long-term patient outcome data beyond planning quality. Synthesizing with WHO's 2020 elimination initiative and a 2023 Lancet Oncology review on global radiotherapy inequities reveals missed connections: AI could prevent over a million deaths annually if scaled, yet risks widening disparities without targeted policy support. Patterns from prior AI deployments in oncology show that workforce augmentation succeeds only when paired with training programs for local physicists.